GLP-1 RAs have been shown to significantly reduce the risk of major adverse cardiovascular events and to slow the progression of chronic kidney disease in clinical trials involving patients with T2D and/or overweight/obesity [5,6,7,84]. This evidence concerns the gene GLP1R and Obesity.